Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 11/20 | 0.49 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5192618 | 0.89 | OGA (0.49) | NOS2HPGDPOLBCYP3A4TSHR | |
| SCHEMBL5190729 | 0.82 | NOS2 (0.63) | NOS2NOS1 | |
| SCHEMBL5190586 | 0.80 | NOS2 (0.54) | NOS2HPGDPOLBNOS1 | |
| SCHEMBL5194454 | 0.79 | NOS2 (0.51) | NOS2HPGDPOLBNOS1 | |
| SCHEMBL5193596 | 0.77 | NOS2 (0.55) | NOS2HPGDPOLBNOS1 | |
| SCHEMBL5193047 | 0.77 | NOS2 (0.65) | NOS2 | |
| SCHEMBL5189995 | 0.77 | OGA (0.56) | NOS2HPGDPOLB | |
| SCHEMBL5194182 | 0.77 | NOS2 (0.57) | NOS2HPGDPOLBNOS1 | |
| SCHEMBL5190648 | 0.77 | POLB (0.47) | NOS2HPGDPOLBMEN1KMT2A | |
| SCHEMBL5190417 | 0.77 | NOS2 (0.67) | NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1754703-A2 | N-Heterocyclic derivatives as nos inhibitors | Berlex, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| EP-0968206-B1 | N-HETEROCYCLIC DERIVATIVES AS NOS INHIBITORS | BERLEX LAB (US) | 2006-11-15 | — | — | EP | disclosed |
| US-6887865-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-05-03 | — | — | US | disclosed |
| US-6864263-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6864368-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLAX LABORATORIES, INC. (US) | 2005-03-08 | — | — | US | disclosed |
| US-6849739-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-6846829-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-6841674-B2 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-6841673-B2 | N-heterocyclic derivatives as nos inhibitors | BERLEX LABORATORIES, INC. (US) | 2005-01-11 | — | — | US | disclosed |
| US-6747031-B2 | MUSCLE RELAXANTS, CONTROLLING IMMUNOLOGY, STROKES, ANTIDIABETIC AGENTS | BERLEX LABORATORIES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-15 | — | — | US | disclosed |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-17 | — | — | US | disclosed |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-04-10 | — | — | US | disclosed |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. | 2002-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073669-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885HPGD 12/4885ALDH1A1 328/4885 |
| US-20020165203-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885HPGD 12/4885ALDH1A1 328/4885 |
| US-20030069210-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885HPGD 12/4885ALDH1A1 328/4885 |
| US-20030083332-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885HPGD 12/4885ALDH1A1 328/4885 |
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | NOS2 2/4885HPGD 11/4885ALDH1A1 333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.